Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Orion Corp New B Shs — FY2025 Earnings Presentation
17 slides from Orion Oyj Class A's earnings presentation, Feb 12, 2026
Slide 1: Orion Full-Year 2025 Result Presentation
Orion Full-Year 2025 Result Presentation 12 February 2026
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Q4 2025 Highlights
Q4 2025 Highlights • EUR 180 million Nubeqa® sales milestone • All business divisions had a strong quarter • R&D pipeline evolving • Initiation of Phase 2 program with ODM-212 • Tenax initiated LEVEL-2 Phase 3 trial with levosimendan 3 12 February 2026 © Orion Corporation
Slide 4: Q4 2025 Financial highlights
Q4 2025 Financial highlights Net sales, EUR million Operating profit, EUR million Operating cash flow per share, EUR Operating profit margin 47.2% (21.3%) +60.1% +253.8% -7.5% 695.3 328.1 0.63 0.58 181.3 434.4 181.3 0.5 +18.5% 514.0 92.7 433.9 0.5 146.8 +59.2% 92.3 Q4/2024 Q4/2025 Q4/2024 Q4/2025 Q4
Slide 5: Net sales bridge (MEUR)
Net sales bridge (MEUR) 8.1 0.4 -0.6 695.3 8.9 4.4 Includes major milestone of EUR 180 million 434.4 239.7 Q4/2024 1 2 3 4 5 6 Q4/2025 1 Innovative Medicines 4 Animal Health 2 Branded Products 5 Fermion 3 Generics and Consumer Health 6 Translation differences and other operations 5 12 February 2026
Slide 6: Operating profit bridge (MEUR)
Operating profit bridge (MEUR) 328.1 -2.1 -3.9 48.5 28.3 -12.3 180.8 92.7 -4.1 Q4/2024 1 2 3 4 5 6 7 Q4/2025 1 Change in sales volume 5 Milestones 2 Changes in prices, COGS and product mix 6 Other operating income and expenses 3 Exchange rate effect on gross margin 7 Fixed cost 4 Royalties 6 12 Febr
Slide 7: 2025 Highlights
2025 Highlights • All-time-high net sales and operating profit • All business divisions performed well • Lots of positive developments in R&D • ARANOTE approvals for Nubeqa® • New license and collaboration agreements • MSD expanding opevesostat development to women’s cancers • New biologics R&D cent
Slide 8: January-December 2025 Financial highlights
January-December 2025 Financial highlights Net sales, EUR million Operating profit, EUR million Operating cash flow per share, EUR Operating profit margin 33.4% (27.0%) +22.5% +51.6% +7.8% 1,889.5 631.6 2.25 183.4 2.09 1,542.4 183.4 133.8 416.6 +21.1% 133.8 1,706.1 +58.5% 1,408.6 448.3 282.8 2024 20
Slide 9: Innovative Medicines
Innovative Medicines +152.3% +54.8% Nubeqa® sales (MEUR) 397.1 812.7 213 180.0 48 166 180.0 22.9 152 525.2 140 48 36 4.5 130.0 44 157.4 26.9 95 92 5.4 609.8 72 26 165 38 +37.9% 212.6 50 21 116 118 368.3 +60.1% 96 152.0 MEUR MEUR 18 69 51 54 32 Q4/2024 Q4/2025 2024 2025 2024 2024 2024 2024 2025 2025
Slide 10: Branded Products
Branded Products +11.2% +9.4% • Easyhaler® budesonide- 88.5 314.6 formoterol the growth driver for 79.6 9.8 287.5 31.6 respiratory therapy area 6.4 24.2 • The rest of the Easyhaler product 28.8 100.2 portfolio impacted negatively by 25.8 93.3 changes in treatment guidelines that favor the use of com
Slide 11: Generics and Consumer Health
Generics and Consumer Health +5.7% +4.6% • New launches and good 150.3 552.8 availability of Orion products in 142.3 528.4 Finland and Scandinavia 34.5 132.1 132.8 supported growth 35.6 115.8 396.3 420.0 106.6 MEUR MEUR Q4/2024 Q4/2025 2024 2025 Generic prescription drugs Consumer Health products 11
Slide 12: Animal Health
Animal Health +1.1% +9.9% • The growth came from various 35.0 35.4 140.9 different products and regions 128.2 MEUR MEUR Q4/2024 Q4/2025 2024 2025 12 12 February 2026 © Orion Corporation
Slide 13: TOP 10 products and net sales split in 2025
TOP 10 products and net sales split in 2025 EUR vs. Product or product portfolio million 2024 1. Nubeqa® 609.8 +65.6% 4% 7% 2. Easyhaler® product portfolio 177.4 +7.1% 3. Entacapone products1 90.5 +7.6% 4. Divina® series 31.6 +30.7% 43% 5. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 31.3 -2.1% 29%
Slide 14: Orion's key clinical development pipeline
Orion’s key clinical development pipeline Invented by Developer(s) Trial/compound Indication Phase I Phase II Phase III ARASTEP (darolutamide) prostate cancer (BCR2) DASL-HiCaP (darolutamide) (Neo-)adjuvant prostate cancer OMAHA-003 (opevesostat) prostate cancer (later-line mCRPC3) OMAHA-004 (opeves
Slide 15: Leveraging diversity for sustainable growth
Leveraging diversity for sustainable growth 4,000+ More than 35+ 8 1,000+ builders of 100 operating countries production sites workers in well-being years of industrial history & experience 44 nationalities 5 R&D centres production, 100 of whom are managers 98% 570+ line managers ~470 92% Code of Co
Slide 16: Outlook for 2026
Outlook for 2026 (provided on 14 January 2026) Net sales EUR 1,900 million–EUR 2,100 million Operating profit EUR 550 million–EUR 750 million 16 12 February 2026 © Orion Corporation
Slide 17: Upcoming events
Upcoming events AGM planned to be held 24/3/2026 Interim Report 1–3/2026 23/4/2026 Half-Year Financial Report 1–6/2026 17/7/2026 Interim Report 1–9/2026 28/10/2026 The Financial Statements and the Report by the Board of Directors for 2025 will be published on the Company's website at the latest in w